Evaluation Exploring Patient Journeys in the Evolving Therapeutic Landscape of Bladder Cancer (Part 1) Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Siamak Daneshmand, MD 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe the burden and impact on quality of life associated with BC 5 4 3 2 1 Evaluate relevant clinical trial data and the most current guideline recommendations for implementation in clinicalpractice 5 4 3 2 1 Incorporate appropriate neoadjuvant and adjuvant BC therapies based upon initial diagnosis, staging, and riskstratification 5 4 3 2 1 Implement strategies to advise patients regarding AE reporting and management to improve treatment adherence and outcomes 5 4 3 2 1 Employ multidisciplinary team strategies to develop a comprehensive treatment plan that addresses patient-centered preferences and facilitates optimal outcomes 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with bladder cancer on a monthly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage bladder cancer. Excellent Very Good Good Fair Poor As recommended by the EAU and AUA/SUO, Bacillus Calmette- Guérin (BCG) therapy has become the standard of adjuvant treatment for which of the following diagnoses? High-risk MIBC following TURBT High-risk MIBC prior to TURBT High-risk NMIBC following TURBT High-risk NMIBC prior to TURBT Which of the following had an FDA black box warning for the treatment-related adverse events (TRAEs) Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)? Enfortumab vedotin Erdafitinib Gemcitabine Sacituzumab How confident are you now in your ability to implement strategies to advise patients regarding AE reporting and management to improve treatment adherence and outcomes? Very confident Confident Somewhat confident Not very confident Not at all confident How often will you employ multidisciplinary team strategies to develop a comprehensive treatment plan that addresses patient-centered preferences and facilitates optimal outcomes for the management of bladder cancer? Always Often Sometimes Rarely Never Based on my participation in this activity, I anticipate I will more often: (select all that apply) Assess the utility of PD-L1 inhibitors, PD-1 inhibitors, FGFR inhibitors, and antibody drug conjugates (ADCs) for the treatment of bladder cancer Evaluate relevant clinical trial data and the most current guideline recommendations for implementation in clinical practice Identify clinical trial opportunities for appropriate patients with BC Incorporate novel and cellular therapies into care plans for appropriate patients with BC Incorporate appropriate neoadjuvant and adjuvant BC therapies based upon initial diagnosis, staging, and risk stratification Remain apprised of the clinical trial data and mechanisms of action associated with novel and investigational treatments for BC Support patient-centered, multidisciplinary strategies for the care of my patients with BC Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max
